← Leaderboards
Wayne A. Marasco
Dana-Farber Cancer Inst
$43,896,916
Attributed
$47,861,521
Total exposure
30
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,861,521 · 30
By mechanism
R01$25,281,594 · 11
U01$15,560,522 · 3
R21$3,609,570 · 8
P50$1,285,701 · 1
R33$997,779 · 1
R56$645,350 · 1
Top collaborators
- Kevin Esvelt6 shared
- Rudolf Jaenisch6 shared
- Styliani Markoulaki6 shared
- Sam R. Telford6 shared
- Corey Taylor Watson2 shared
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesEpitopesIn VitroIn VivoCellsGenesBaseNeutralizing AntibodyResponseB-LymphocytesVirusEpitope MappingInfectionProteinsCell LinePreventImmunizationImmunityBinding (Molecular Function)Clinical ResearchImmuneT-LymphocyteVaccinesPathogen
Grant awards (87)
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness$1,169,078
U01 · FY2025 · AI · contact PI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$825,096
R01 · FY2025 · AI
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness$1,173,350
U01 · FY2024 · AI · contact PI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$854,479
R01 · FY2024 · AI
In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity$268,059
R21 · FY2024 · CA · contact PI
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness$1,176,696
U01 · FY2023 · AI · contact PI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$881,046
R01 · FY2023 · AI
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2$874,734
R01 · FY2023 · AI · contact PI
Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness$1,238,693
U01 · FY2022 · AI · contact PI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$904,332
R01 · FY2022 · AI
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2$876,907
R01 · FY2022 · AI · contact PI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$235,144
R01 · FY2022 · AI
Heritable immunization of the white-footed mouse reservoir of Lyme disease$957,529
R01 · FY2021 · AI
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV2$903,360
R01 · FY2021 · AI · contact PI
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses$688,901
R01 · FY2020 · AI · contact PI
The role of Ig Polymorphism in shaping the Broadly Neutralizing Antibody Response to Hemagglutinin HA stem domain(s) of Influenza A, Group 1 and 2 Viruses$222,500
R21 · FY2020 · AI · contact PI
Population level characterization of human immunoglobulin heavy chain germline variants with impacts on variability in the Ab repertoire of healthy adults$119,578
R21 · FY2020 · AI
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses$917,070
R01 · FY2019 · AI · contact PI
Population level characterization of human immunoglobulin heavy chain germline variants with impacts on variability in the Ab repertoire of healthy adults$357,431
R21 · FY2019 · AI
The role of Ig Polymorphism in shaping the Broadly Neutralizing Antibody Response to Hemagglutinin HA stem domain(s) of Influenza A, Group 1 and 2 Viruses$267,000
R21 · FY2019 · AI · contact PI
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses$847,609
R01 · FY2018 · AI · contact PI
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses$834,149
R01 · FY2017 · AI · contact PI
Studies of IGHV Germline Gene Polymorphism, Utilization & Shifting for Seasonal Influenza Vaccine Induced Broadly Neutralizing Antibody Responses$756,432
R01 · FY2016 · AI · contact PI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses$1,078,057
R01 · FY2014 · AI · contact PI
Structural Requirements for Broadly Protecting Antibodies to Influenza A & B$645,350
R56 · FY2014 · AI · contact PI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses$1,025,389
R01 · FY2013 · AI · contact PI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses$1,103,251
R01 · FY2012 · AI · contact PI
SPORE Core 1: Administrative, Evaluation and Planning$238,452
P50 · FY2012 · CA · contact PI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza$1,430,391
U01 · FY2011 · AI · contact PI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses$1,117,743
R01 · FY2011 · AI · contact PI
SPORE Core 1: Administrative, Evaluation and Planning$270,189
P50 · FY2011 · CA · contact PI
Study of broadly neutralizing antibody generation to HIV gp140 in humanized mice$159,125
R21 · FY2011 · AI · contact PI
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY AGAINST SHIV IN RHESUS MACAQUES$68,415
P51 · FY2011 · RR · contact PI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza$1,444,744
U01 · FY2010 · AI · contact PI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses$1,093,892
R01 · FY2010 · AI · contact PI
Novel Vaginal Microbicides Based On Stable AAV-Neutralizing Antibody Gene Transfe$997,779
R33 · FY2010 · AI · contact PI
SPORE Core 1: Administrative, Evaluation and Planning$280,414
P50 · FY2010 · CA · contact PI
Study of broadly neutralizing antibody generation to HIV gp140 in humanized mice$272,982
R21 · FY2010 · AI · contact PI
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY AGAINST SHIV IN RHESUS MACAQUES$65,759
P51 · FY2010 · RR · contact PI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza$1,309,684
U01 · FY2009 · AI · contact PI
SPORE Core 1: Administrative, Evaluation and Planning$279,688
P50 · FY2009 · CA · contact PI
Novel Vaginal Microbicides Based On Stable AAV-Neutralizing Antibody Gene Transfe$209,564
R21 · FY2009 · AI · contact PI
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY AGAINST SHIV IN RHESUS MACAQUES$111,945
P51 · FY2009 · RR · contact PI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza$1,378,013
U01 · FY2008 · AI · contact PI
Human Antibodies and Targeted Vaccines Against SARS-CoV$709,379
U01 · FY2008 · AI · contact PI
Studies of CCR5 Conformational Heterogeneity & HIV Entry$357,882
R01 · FY2008 · AI · contact PI
Role of SHP-1 Deregulation in HTLV-1 Leukemogenesis$255,370
R01 · FY2008 · CA · contact PI
Novel Vaginal Microbicides Based On Stable AAV-Neutralizing Antibody Gene Transfe$254,065
R21 · FY2008 · AI · contact PI
Generation of a Therapeutic Antibody Directed Against CCR4 for Patients with$216,958
P50 · FY2008 · CA · contact PI
Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza$1,594,408
U01 · FY2007 · AI · contact PI
Human Antibodies and Targeted Vaccines Against SARS-CoV$700,465
U01 · FY2007 · AI · contact PI
Human Anti-Macaque CCR5 Mabs for Passive Immunotherapy$403,328
R01 · FY2007 · AI · contact PI
Studies of CCR5 Conformational Heterogeneity & HIV Entry$364,813
R01 · FY2007 · AI · contact PI
Role of SHP-1 Deregulation in HTLV-1 Leukemogenesis$255,370
R01 · FY2007 · CA · contact PI
Human Antibodies and Targeted Vaccines Against SARS-CoV$694,504
U01 · FY2006 · AI · contact PI
Human Anti-Macaque CCR5 Mabs for Passive Immunotherapy$415,374
R01 · FY2006 · AI · contact PI
Studies of CCR5 Conformational Heterogeneity & HIV Entry$375,709
R01 · FY2006 · AI · contact PI
Role of SHP-1 Deregulation in HTLV-1 Leukemogenesis$262,996
R01 · FY2006 · CA · contact PI
Genetic Retargeted Human T-cells for RCC Immunotherapy$245,026
R21 · FY2006 · DK · contact PI
Human Antibodies and Targeted Vaccines Against SARS-CoV$691,466
U01 · FY2005 · AI
Human Anti-Macaque CCR5 Mabs for Passive Immunotherapy$425,370
R01 · FY2005 · AI
Studies of CCR5 Conformational Heterogeneity &HIV Entry$384,750
R01 · FY2005 · AI
Role of SHP-1 Deregulation in HTLV-1 Leukemogenesis$269,325
R01 · FY2005 · CA
Genetic Retargeted Human T-cells for RCC Immunotherapy$212,500
R21 · FY2005 · DK
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY AGAINST SHIV IN RHESUS MACAQUES$69,059
P51 · FY2005 · RR
Human Antibodies and Targeted Vaccines Against SARS-CoV$849,651
U01 · FY2004 · AI
Human Anti-Macaque CCR5 Mabs for Passive Immunotherapy$425,370
R01 · FY2004 · AI
Studies of CCR5 Conformational Heterogeneity &HIV Entry$384,750
R01 · FY2004 · AI
Role of SHP-1 Deregulation in HTLV-1 Leukemogenesis$269,325
R01 · FY2004 · CA
Targeting Human Cyclin T1 to Inhibit HIV-1 Replication$254,370
R21 · FY2004 · AI
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY$64,424
P51 · FY2004 · RR
Role of Grb3-3 in T-cell Activation &HIV-1 Replication$309,713
R01 · FY2003 · AI
Global Analysis of Transcriptional Deregulation by HIV-1$256,500
R21 · FY2003 · AI
Targeting Human Cyclin T1 to Inhibit HIV-1 Replication$254,370
R21 · FY2003 · AI
Human Anti-Macaque CCR5 Mabs for Passive Immunotherapy$211,620
R01 · FY2003 · AI
ANTI-HIV-1 TAT HUMAN SFV INTRABODY GENE THERAPY AGAINST SHIV IN RHESUS MACAQUES$101,403
P51 · FY2003 · RR
Role of Grb3-3 in T-cell Activation &HIV-1 Replication$340,950
R01 · FY2002 · AI
GENE THERAPY BY PHENOTYPIC KNOCKOUT OF HIV CORECEPTORS$332,376
R01 · FY2002 · AI
Global Analysis of Transcriptional Deregulation by HIV-1$256,500
R21 · FY2002 · AI
INTRACEULLULAR ANTI-TAT ANTIBODIES FOR AIDS GENE THERAPY$211,722
R01 · FY2002 · AI
HUMAN ANTITAT INTRABODY GENE THERAPY AGAINST SHIV$422,392
R01 · FY2001 · RR
Role of Grb3-3 in T-cell Activation &HIV-1 Replication$341,983
R01 · FY2001 · AI
GENE THERAPY BY PHENOTYPIC KNOCKOUT OF HIV CORECEPTORS$322,698
R01 · FY2001 · AI
INTRACEULLULAR ANTI-TAT ANTIBODIES FOR AIDS GENE THERAPY$212,332
R01 · FY2001 · AI
HUMAN ANTITAT INTRABODY GENE THERAPY AGAINST SHIV$425,086
R01 · FY2000 · RR
GENE THERAPY BY PHENOTYPIC KNOCKOUT OF HIV CORECEPTORS$313,296
R01 · FY2000 · AI
INTRACEULLULAR ANTI-TAT ANTIBODIES FOR AIDS GENE THERAPY$212,574
R01 · FY2000 · AI